CRISPR PATENT LANDSCAPE - IPStudies · EU Horizon2020 expert on Innovation in SMEs 2013-2015 •...

Preview:

Citation preview

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017 IPStudies SARL

CRISPRPATENTLANDSCAPEAugust2017

Intangibleassets deserve closer scrutiny

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Copyright

• Unless otherwise specified, all content included on this document, such astext, graphics, logos, button icons, images, audio and video clips, digitaldownloads, data compilations, and software, including but not limited toIPStudies surveys, is the property of IPStudies SARL and protected byinternational copyright laws.

• You agree not to copy, reproduce, duplicate, sell, resell, or exploit for anycommercial purposes, any portion of this content.

• You may not re-use and/or extract part of this content outside of your legalentity, institutional or corporate environment without IPStudies’s expressconsent in writing.

2

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Ourteam

3

CorinneLEBUHAN,PhDICTExpertIPStrategy&Management

• FundedIPStudiesin2010tohelpSwiss&EUhigh-techSMEsdevelopandexecutetheirIPvaluationplansusingthelatestpatentanalyticstoolsandtrends

• 15yearsexperienceinIPstrategyandmanagement– formerVPKnowledgeManagementofNagravision-Kudelski Group,inchargewithpatents(200families),standards,R&Dcollaborations,licensingandtechnicalpublicationsportfolios

• TeachesinternationallicensingpracticesandIPstrategyatIEEPI–EUHorizon2020expertonInnovationinSMEs2013-2015

• ICTTechnologyExpertforvariouslicensingfacilitatorsandaggregatorsinFrance,GermanyandtheUS

• Universitypostgraduateinmanagementofinnovationandintellectualproperty(UniversityofStrasbourg,2008),PhDinCommunicationsScience(EPFL,1998),MsC inElectricalEngineering(INSARennes,1994)

• ExperiencedwithPatbase,EPO/RegisterPlus,USPTO/PAIR

• InternationalnetworkofIPpractitionersandlicensingmanagers-MemberLES,IEEE,AROPI,AAIEEPI

FabienPALAZZOLI,PhDLifeSciencesExpertPatentAnalysis&Landscapes

• JoinedIPStudies in2013todeveloptheIPanalyticsofferinginlifesciences&biotechnology

• 9+yearsexperienceintechnologytransfers,patentmapping/landscapingandFTO-drivenresearchintelligencefortheFrenchpublicsectorandbiotechSMEs- formerIPanalyticssalesmanagerforFISTSA,theCNRStechnologytransferoffice

• Author/co-authorof18scientificandtechnicalpublications/communications,aswellasonebookchapter

• Lifesciencespatentanalystforvariousbiotech/medtech SMEsinSwitzerlandandinEurope

• PhDinLifeSciences(Exploitationofpatentinformationinapublicresearchlaboratory:identificationoftechnologicalnichesinbioproduction andgenetherapy,UniversityofTours,2011),MsC inBiotechnologyandLaw(UniversityofTours,2007)

• ExperiencedwithOrbit,Patbase,Intellixir,patentofficesdatabases

• Internationalnetworkofpatentinformationanalysts

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Tableofcontents

4

• Methodology

• OveralltrendsoftheCRISPRpatentdatabase• Temporaldistributionofpatentfilings(2002-2017)• Temporaldistributionofpatentfilingsbytypeofplayers(2002-2017)• Worldmapofpriorityfilings• Temporaldistributionofpriorityfilings(2002-2017)• Worldmapofpatentextensions• Mainpatentapplicants/assigneesandtemporaldistributionoftheirfilings• Co-filingsbetweenapplicants/assignees

• BreakdownoftheCRISPRpatentdatabase• BreakdownbyClaimcoverageofpatentfamilies

• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningofapplicants/assignees

• BreakdownbyComponents• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningoftheapplicants/assignees

• BreakdownbyChimericproteins• Breakdownofthepatentportfolio• Temporaldistributionoffilings• Positioningofapplicants/assignees

• Mainforwardcitedpatentfamilies• Appendice1– Licensingannouncements• Appendice2– Affiliationmappingofplayerspresentinthepatentlandscape

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-20175

Temporaldistributionofpatentfilingsbytypeofplayers(2002-2017)

Ø 1043 filings by institutional applicants/assignees (60.5%),Ø 553 filings by industrial applicants/assignees (32.1%),Ø 74 filings by individual inventors (4.3%),Ø 57 co-filings between industrial applicants/assignees and institutional applicants/assignees (3.3%).Ø The years 2016 and 2017 are not complete due to the delay of publication of 18 months.

1724patentfamilies

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-20176

Mainpatentapplicants/assignees (≥12patentfamilies)

Institutional applicant/assignee

Industrial applicant/assignee

Ø Affiliates & subsidiaries have been gathered under their parent company (Danisco with DuPont…). Co-filings arecounted for each co-owner: a patent application co-filed between the MIT, the Harvard University and theBroad Institute is counted once for each of this applicant.

Ø The patent portfolio of DuPont comprises historical patent families on CRISPR sequences dealing with the typingof bacterial strains, cultures with improved phage resistance and applications for preparing food.

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Temporaldistributionoffilingsofmainapplicants/assignees(≥12patentfamilies)

7

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Co-filingsbetweenapplicants/assignees(≥2co-filings)

8

Number ofpatentfamiliesintheportfolio

Co-filing(s)betweenthetwo applicants

Ø The co-filing map shows the co-filings between applicants/assignees. The same type of link can be found whenan assignment occurred between two players, giving the historical applicants as well as the new owners.

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-20179

BreakdownoftheCRISPRpatentdatabase(1)

Ø A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’and ‘Human cell-subject’ and ‘CRISPR-Cas system’…).

• Genomeediting

• Transcriptional-epigeneticregulation

• Otherapplication

• Therapeutics-Diagnostics

• Bioproduction

• Drugscreening

• Modifiedcell

• Modifiedanimal

• Modifiedplant

Applications

• Humancell-subjet

• Mammaliancell-organism

• Otheranimalcell-organism

• Plantcell-organism

• Fungi-algae-yeast

• Eukaryoticcell-organism

• Prokaryoticcell

• Otherorganism

• Undefinedcell-organism

Cells/Organisms

• Nuclease

• ZFNuclease-ZFP

• Meganuclease

• TALENuclease-TALEP

• gRNA-guidesequence

• Cas-CRISPRenzyme

• CRISPRsystem

• Otherchimericprotein

• Vector-Delivery

• CRISPRsequence

‘Moleculartools’

‘CLAIMCOVERAGE’

The1724patentfamilies havebeenmanually classified

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-201710

BreakdownoftheCRISPRpatentdatabase(2)

Ø A patent family can be classified in several categories (e.g. ‘Genome Editing’ and ‘Therapeutic application’and ‘Human cell-subject’ and ‘CRISPR-Cas system’…).

COMPONENTS CHIMERICPROTEINS

Chimericnucleases

• Undefinednucleases

• ZFNucleases

• Meganucleases

• TALENucleases

• RNA-GuidedNucleases

• Otherchimericnucleases

Otherchimericproteins

The1724patentfamilies havebeenmanually classified

• Cas-CRISPRenzyme

• MutatedCas - nickase

• dCas

• Cas9

• mutatedCas9- nickase

• dCas9

• OtherCas

• OthermutatedCas

• Cpf1-mutatedCpf1

• gRNA

• sgRNA-chiRNA

• crRNA

• tracrRNA

• Nuclease-Nickase

• Meganuclease

• Integrase

• Recombinase

• Repressor-Activator

• Acetyltransferase

• Deacetylase

• Methyltransferase

• Demethylase

• Kinase

• Othercatalyticdomain

• Undefinedcatalyticdomain

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

BreakdownbyClaimcoverageofpatentfamiliesBreakdownofthepatentportfolio

11

Applications Cell /Organism ‘Covered molecular tools’

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

BreakdownbyClaimcoverageofpatentfamiliesPositioningofmainapplicants/assignees(≥12patentfamilies)

12

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

BreakdownbyComponentsBreakdownofthepatentportfolio

13

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

BreakdownbyComponentsPositioningofmainapplicants/assignees(≥12patentfamilies)

14

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

BreakdownbyChimericproteinsBreakdownofthepatentportfolio

15

Nucleases including chimeric nucleases Other chimeric proteins

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

BreakdownbyChimericproteinsPositioningofmainapplicants/assignees(≥12patentfamilies)

16

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-201717

Licenseannouncements(samplepage4)

Licensor Scope Licensee Date

Toolgen

Worldwidelicense&sublicensesrightsforresearchapplicationsincludingthedevelopmentandsaleofreagents,celllines,andanimalmodels,aswellasrightsforhighthroughputscreening,diagnostics,andbioproduction.ToolGen retainsitsrightsinbroadareasincludinghighthroughputscreening,diagnostics,bioproduction,plantbiotechnologyandgene/celltherapy.

ThermoFisher Scientific 2015/03

VilniusUniversityExclusiverights tothe Cas9-mediatedgenomeeditingintellectualpropertyownedbyVilniusUniversityforallcommercialuses,includinginagriculture.

DuPont 2015/06

UniversityofMinnesota

Exclusiveworldwiderights toanAAVgenetherapyandintellectualpropertyfromtheUniversityofMinnesotatotreatpatientswithFanconianemia(FA)disorderandotherrareblooddiseasesusingtheCRISPR/cas9technology platform.

AbeonaTherapeuticsInc 2015/06

CaribouBiosciencesDupont(incl.VilniusUniversity)

Multi-faceted agreementincludes thecross-licensing ofkeyIP,aresearch collaboration,andfinancial investments byDuPont inCariboutodevelopandutilizeCRISPR-Castechnologyforproductdevelopmentinmultiplefieldsincludinghumanandanimaltherapeutics,diagnostics,industrialbiotechnology,researchtools,andcertainagriculturesegments.TheDuPontlicensetoCaribouincludesrightstotheCas9-mediatedgenomeediting IPownedbyVilniusUniversityandexclusivelylicensedtoDuPont inmultiplefields and exclusiveaccess intheresearch tools field.

CaribouBiosciencesDuPont(incl.VilniusUniversity)

2015/10

CrisprTherapeutics

$105millionupfront—$75millionincash,$30millionequityinvestment- futuredevelopment,regulatoryandsalesmilestonesofupto$420millionforeachofuptosixCRISPR-Cas9-basedtreatmentsforwhichVertexhasagreedtolicenseexclusivedevelopmentrights (incl.cystic fibrosis).Royaltiesonfuturesales.

Vertex 2015/10

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Furtheranalyticsforyourspecificneedswiththeonlinedatabase

• Zoomonpatentportfoliosofspecificapplicants

• Zoomonpatentsfiledinacountry/region(US,EP,CN…),withinatimeperiod

• Zoomonpatentscoveringanapplication,adedicatedtechnology,aspecificationorafunctionalsubset

• Linktoonlinepatentofficeregisterstoreviewlatestlegalstatus

18

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Accesstotheinteractive“navigate,zoom,clickandshowpatent”database

19

4

1

2

3

CRISPR Patent Landscape – SAMPLE – August 2017 ©2014-2017

Order

20

This is only a sample report with partial data. Our fulloffer includes:• ananalysisofthepatentlandscape,covering1724patentfamilies,worldwide• asynthesisofIPstrategyfindings,tovisualizekeytrendsintermsofpatentapplicants,collaborationnetworks,competitortechnologypositioning,keyinventorsandR&Dwhitespacesoutofthelandscape• anon-lineaccesstothe1724patentfamiliesset,soyoucanvisualize,navigate,focusandextractthemostrelevantpatentdataaccordingtoyourspecificneeds.

Contactustodayforanofferatsales@ipstudies.ch+41797875746

Recommended